<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37072752</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2164</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>18</Day></PubDate></JournalIssue><Title>BMC genomics</Title><ISOAbbreviation>BMC Genomics</ISOAbbreviation></Journal><ArticleTitle>Restoration of aberrant gene expression of monocytes in systemic lupus erythematosus via a combined transcriptome-reversal and network-based drug repurposing strategy.</ArticleTitle><Pagination><StartPage>207</StartPage><MedlinePgn>207</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">207</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12864-023-09275-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Monocytes -key regulators of the innate immune response- are actively involved in the pathogenesis of systemic lupus erythematosus (SLE). We sought to identify novel compounds that might serve as monocyte-directed targeted therapies in SLE.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We performed mRNA sequencing in monocytes from 15 patients with active SLE and 10 healthy individuals. Disease activity was assessed with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2&#xa0;K). Leveraging the drug repurposing platforms iLINCS, CLUE and L1000CDS<sup>2</sup>, we identified perturbagens capable of reversing the SLE monocyte signature. We identified transcription factors and microRNAs (miRNAs) that regulate the transcriptome of SLE monocytes, using the TRRUST and miRWalk databases, respectively. A gene regulatory network, integrating implicated transcription factors and miRNAs was constructed, and drugs targeting central components of the network were retrieved from the DGIDb database. Inhibitors of the NF-&#x3ba;B pathway, compounds targeting the heat shock protein 90 (HSP90), as well as a small molecule disrupting the Pim-1/NFATc1/NLRP3 signaling axis were predicted to efficiently counteract the aberrant monocyte gene signature in SLE. An additional analysis was conducted, to enhance the specificity of our drug repurposing approach on monocytes, using the iLINCS, CLUE and L1000CDS<sup>2</sup> platforms on publicly available datasets from circulating B-lymphocytes, CD4<sup>+</sup> and CD8<sup>+</sup> T-cells, derived from SLE patients. Through this approach we identified, small molecule compounds, that could potentially affect more selectively the transcriptome of SLE monocytes, such as, certain NF-&#x3ba;B pathway inhibitors, Pim-1 and SYK kinase inhibitors. Furthermore, according to our network-based drug repurposing approach, an IL-12/23 inhibitor and an EGFR inhibitor may represent potential drug candidates in SLE.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Application of two independent - a transcriptome-reversal and a network-based -drug repurposing strategies uncovered novel agents that might remedy transcriptional disturbances of monocytes in SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Nikolakis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Amsterdam Institute for Gastroenterology Endocrinology and Metabolism, Department of Gastroenterology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology &amp; Immunology Center (ARC), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection &amp; Immunity, Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Onassis Foundation, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Garantziotis</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Autoimmunity and Inflammation, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sentis</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Autoimmunity and Inflammation, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanouriakis</LastName><ForeName>Antonis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology Unit, Department of Internal Medicine, Attikon University Hospital, Athens, 4th, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Propaedeutic Internal Medicine, "Laiko" General Hospital, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Academic Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertsias</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Medical School, University Hospital of Heraklion, University of Crete, Heraklion, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Biology and Biotechnology-FORTH, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frangou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Autoimmunity and Inflammation, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Limassol General Hospital, Limassol, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, University of Nicosia, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolopoulos</LastName><ForeName>Dionysis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Autoimmunity and Inflammation, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology Unit, Department of Internal Medicine, Attikon University Hospital, Athens, 4th, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Banos</LastName><ForeName>Aggelos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Autoimmunity and Inflammation, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Boumpas</LastName><ForeName>Dimitrios T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Laboratory of Autoimmunity and Inflammation, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. boumpasd@uoc.gr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology Unit, Department of Internal Medicine, Attikon University Hospital, Athens, 4th, Greece. boumpasd@uoc.gr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Academic Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece. boumpasd@uoc.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>742390</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Genomics</MedlineTA><NlmUniqueID>100965258</NlmUniqueID><ISSNLinking>1471-2164</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drug repurposing</Keyword><Keyword MajorTopicYN="N">Micro RNAs</Keyword><Keyword MajorTopicYN="N">Monocytes</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Transcription factors</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>23</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37072752</ArticleId><ArticleId IdType="pmc">PMC10114456</ArticleId><ArticleId IdType="doi">10.1186/s12864-023-09275-8</ArticleId><ArticleId IdType="pii">10.1186/s12864-023-09275-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ma W-T, Gao F, Gu K, Chen D-K. The role of Monocytes and Macrophages in Autoimmune Diseases: a Comprehensive Review. Front Immunol. 2019;10:1140. doi: 10.3389/fimmu.2019.01140.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01140</ArticleId><ArticleId IdType="pmc">PMC6543461</ArticleId><ArticleId IdType="pubmed">31178867</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol. 2002;103:54&#x2013;62. doi: 10.1006/clim.2001.5172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clim.2001.5172</ArticleId><ArticleId IdType="pubmed">11987985</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigai M, Hara M, Fukasawa C, Nakazawa S, Kawaguchi Y, Kamatani N, et al. Responsiveness of peripheral blood B cells to recombinant CD40 ligand in patients with systemic lupus erythematosus. Lupus. 1999;8:227&#x2013;33. doi: 10.1191/096120399678847678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399678847678</ArticleId><ArticleId IdType="pubmed">10342716</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi T, Aiba Y, Nomura T, Matsuda J, Mochida K, Suzuki M, et al. Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol. 2002;168:9&#x2013;12. doi: 10.4049/jimmunol.168.1.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.1.9</ArticleId><ArticleId IdType="pubmed">11751940</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Huang W, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K, et al. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum. 2003;48:495&#x2013;506. doi: 10.1002/art.10929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10929</ArticleId><ArticleId IdType="pubmed">12571860</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Lee PY, Reeves WH. (2010). Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz). 2010 Oct;58(5):355 &#x2013; 64. doi: 10.1007/s00005-010-0093-y. Epub 2010 Jul 31. PMID: 20676786; PMCID: PMC3785254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785254</ArticleId><ArticleId IdType="pubmed">20676786</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. (1998). Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 41:1241&#x2013;50. doi: 10.1002/1529-0131(199807)41:7&lt;1241::AID-ART15&gt;3.0.CO;2-H.</Citation><ArticleIdList><ArticleId IdType="pubmed">9663482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavai M, Szegedi G. (2007). Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. Autoimmun Rev. (2007) 6:497&#x2013;502. doi: 10.1016/j.autrev.2007.01.017.</Citation><ArticleIdList><ArticleId IdType="pubmed">17643939</ArticleId></ArticleIdList></Reference><Reference><Citation>Umare V, Pradhan V, Nadkar M, Rajadhyaksha A, Patwardhan M, Ghosh KK et al. (2014). Effect of proinflammatory cytokines (IL-6, TNF-alpha, and IL-1beta) on clinical manifestations in Indian SLE patients. Mediators Inflamm. 2014:385297. doi: 10.1155/2014/385297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273527</ArticleId><ArticleId IdType="pubmed">25548434</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin O, Sun LY, Zhou KX, Zhang XS, Feng XB, Mok MY, et al. Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus. Clin Rheumatol. 2005;24:107&#x2013;10. doi: 10.1007/s10067-004-0972-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-004-0972-x</ArticleId><ArticleId IdType="pubmed">15818511</ArticleId></ArticleIdList></Reference><Reference><Citation>Santer DM, Yoshio T, Minota S, Moller T, Elkon KB. (2009). Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol. (2009) 182:1192&#x2013;201. doi: 10.4049/jimmunol.182.2.1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745922</ArticleId><ArticleId IdType="pubmed">19124763</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnblom L, Leonard D. (2016). Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Science &amp; Medicine 2019;6:e000270. doi:10.1136/lupus-2018-000270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Q, Reid SP, Clark NR, Wang Z, Fernandez NF, Rouillard AD, Readhead B, Tritsch SR, Hodos R, Hafner M et al. (2016). L1000CDS2: LINCS L1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2016;2:16015. doi: 10.1038/npjsba.2016.15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389891</ArticleId><ArticleId IdType="pubmed">28413689</ArticleId></ArticleIdList></Reference><Reference><Citation>Garantziotis P, Nikolakis D, Doumas S, Frangou E, Sentis G, Filia A, Fanouriakis A, Bertsias G, Boumpas DT. 2022. Molecular Taxonomy of Systemic Lupus Erythematosus Through Data- Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.860726</ArticleId><ArticleId IdType="pmc">PMC9125979</ArticleId><ArticleId IdType="pubmed">35615355</ArticleId></ArticleIdList></Reference><Reference><Citation>Frangou E, Garantziotis P, Grigoriou M, Banos A, Nikolopoulos D, Pieta A, Doumas SA, Fanouriakis A, Hatzioannou A, Manolakou T, Alissafi T, Verginis P, Athanasiadis E, Dermitzakis E, Bertsias G, Filia A, Boumpas DT. (2022). Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis. Annals of the rheumatic diseases, annrheumdis-2021-222069. Advance online publication. 10.1136/annrheumdis-2021-222069</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484391</ArticleId><ArticleId IdType="pubmed">35906002</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin N, Wang Q, Zhang X, Jiang D, Cheng H, Zhu K. (2011). The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus. Int Immunopharmacol. 2011;11(9):1319&#x2013;1326. doi:10.1016/j.intimp.2011.04.015.</Citation><ArticleIdList><ArticleId IdType="pubmed">21549858</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez D, Perl A. (2010). mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?. Discov Med. 2010;9(46):173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131182</ArticleId><ArticleId IdType="pubmed">20350481</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafael-Vidal C, Altab&#xe1;s I, P&#xe9;rez N, Mourino RC, Pego-Reigosa JM, Garcia S. (2021). Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis. Int J Mol Sci. 2021;22(3):1263. Published 2021 Jan 27. doi:10.3390/ijms22031263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7865978</ArticleId><ArticleId IdType="pubmed">33514066</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Zhang L, Joo D, et al. NF-&#x3ba;B signaling in inflammation. Sig Transduct Target Ther. 2017;2:17023. doi: 10.1038/sigtrans.2017.23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sigtrans.2017.23</ArticleId><ArticleId IdType="pmc">PMC5661633</ArticleId><ArticleId IdType="pubmed">29158945</ArticleId></ArticleIdList></Reference><Reference><Citation>Darwish N, Sudha T, Godugu K, Bharali DJ, Elbaz O, El-Ghaffar H, Azmy E, Anber N, Mousa SA. Novel targeted Nano-Parthenolide molecule against NF-kB in Acute myeloid leukemia. Molecules. 2019;24(11):2103. doi: 10.3390/molecules24112103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24112103</ArticleId><ArticleId IdType="pmc">PMC6600366</ArticleId><ArticleId IdType="pubmed">31163672</ArticleId></ArticleIdList></Reference><Reference><Citation>Doerner JL, Wen J, Xia Y et al. (2015). TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus. J Invest Dermatol. 2015;135(8):1986&#x2013;1995. doi:10.1038/jid.2015.124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4504782</ArticleId><ArticleId IdType="pubmed">25826425</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu R, Xia Y, Li M et al. (2019). Pim-1 as a Therapeutic Target in Lupus Nephritis. Arthritis Rheumatol. 2019;71(8):1308&#x2013;1318. doi:10.1002/art.40863.</Citation><ArticleIdList><ArticleId IdType="pubmed">30791224</ArticleId></ArticleIdList></Reference><Reference><Citation>Mike EV, Makinde HM, Der E et al. (2018). Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling. Front Immunol. 2018;9:2189. Published 2018 Sep 26. doi:10.3389/fimmu.2018.02189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168636</ArticleId><ArticleId IdType="pubmed">30319641</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon KB, Stone VV. (2011). Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res. 2011;31(11):803&#x2013;812. doi:10.1089/jir.2011.0045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216059</ArticleId><ArticleId IdType="pubmed">21859344</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L, Jiang L, Wang B, Hu Q, Deng S, Huang J, Sun X, Zhang Y, Feng L, Chen W. (2022). Novel microRNA biomarkers of systemic lupus erythematosus in plasma: miR-124-3p and miR-377-3p. Clin Biochem. 2022 May 19:S0009-9120(22)00133-3. doi: 10.1016/j.clinbiochem.2022.05.004. Epub ahead of print. PMID: 35598633.</Citation><ArticleIdList><ArticleId IdType="pubmed">35598633</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhou JP, Chen SJ, Huang HY, Lin WW, Huang DY, Tzeng SJ. (2017). Upregulation of Fc&#x3b3;RIIB by resveratrol via NF-&#x3ba;B activation reduces B-cell numbers and ameliorates lupus. Exp Mol Med. 2017;49(9):e381. Published 2017 Sep 29. doi:10.1038/emm.2017.144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5628277</ArticleId><ArticleId IdType="pubmed">28960214</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannu N, Bhatnagar A. (2020). Combinatorial therapeutic effect of resveratrol and piperine on murine model of systemic lupus erythematosus. Inflammopharmacology.2020;28(2):401&#x2013;424. doi:10.1007/s10787-019-00662-w.</Citation><ArticleIdList><ArticleId IdType="pubmed">31732838</ArticleId></ArticleIdList></Reference><Reference><Citation>Voloshyna I, Teboul I, Littlefield MJ et al. (2016). Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux. Exp Biol Med (Maywood). 2016;241(14):1611&#x2013;1619. doi:10.1177/1535370216647181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4994911</ArticleId><ArticleId IdType="pubmed">27190277</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Sarfert R, Klotsche J, K&#xfc;hl AA, Rubbert-Roth A, Lorenz HM et al. (2014). The Proteasome Inhibitior Bortezomib Depletes Plasma Cells and Ameliorates Clinical Manifestations of Refractory Systemic Lupus Erythematosus. Ann Rheum Dis (2015) 74(7):1474&#x2013;8. doi: 10.1136/annrheumdis-2014-206016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4484251</ArticleId><ArticleId IdType="pubmed">25710470</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Li H, Zhang M et al. (2016). Quercitrin ameliorates the development of systemic lupus erythematosus-like disease in a chronic graft-versus-host murine model. Am J Physiol Renal Physiol. 2016;311(1):F217-F226. doi:10.1152/ajprenal.00249.2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">26911849</ArticleId></ArticleIdList></Reference><Reference><Citation>Toro-Dom&#xed;nguez D, Lopez-Dom&#xed;nguez R, Garc&#xed;aMoreno A, Villatoro-Garc&#xed;a JA, Martorell-Marug&#xe1;n J, Goldman D, Petri M, Wojdyla D, Pons-Estel BA, Isenberg D, Morales-Montes de Oca G, Trejo-Zambrano MI, Garc&#xed;aGonz&#xe1;lez B, Rosetti F, G&#xf3;mez-Mart&#xed;n D, Romero-D&#xed;az J, Carmona-S&#xe1;ez P, Alarc&#xf3;n-Riquelme ME. (2019). Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification. SciRep. 2019 Oct 29;9(1):15502. doi: 10.1038/s41598-019-51616-9. PMID: 31664045; PMCID: PMC6820741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820741</ArticleId><ArticleId IdType="pubmed">31664045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. 2014;14:392&#x2013;404. doi: 10.1038/nri3671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3671</ArticleId><ArticleId IdType="pubmed">24854589</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S. (2018). Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018 Oct 13;392(10155):1330&#x2013;1339. doi: 10.1016/S0140-6736(18)32167-6. Epub 2018 Sep 21. PMID: 30249507.</Citation><ArticleIdList><ArticleId IdType="pubmed">30249507</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven RF, Kalunian KC, D&#xf6;rner T, Hahn BH, Tanaka Y, Gordon RM, Shu C, Fei K, Gao S, Seridi L, Gallagher P, Lo KH, Berry P, Zuraw QC. (2022). Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Annals of the rheumatic diseases, annrheumdis-2022-222858. Advance online publication. 10.1136/ard-2022-222858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9606504</ArticleId><ArticleId IdType="pubmed">35798534</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito K, Kukita K, Kutomi G, Okuya K, Asanuma H, Tabeya T et al. (2015). Heat shock protein 90 associates with Toll-like receptors 7/9 and mediates self-nucleic acid recognition in SLE. Eur J Immunol. 2015;45:2028&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">25871979</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimp S, Chafin C, Regna N, et al. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2012;9:255&#x2013;66. doi: 10.1038/cmi.2012.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2012.5</ArticleId><ArticleId IdType="pmc">PMC4012849</ArticleId><ArticleId IdType="pubmed">22543833</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ye J, Shin Ogawa L, Inoue T, Huang Q, Chu J, et al. The HSP90 inhibitor Ganetespib alleviates Disease Progression and augments intermittent Cyclophosphamide Therapy in the MRL/lpr mouse model of systemic Lupus Erythematosus. PLoS ONE. 2015;10(5):e0127361. doi: 10.1371/journal.pone.0127361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127361</ArticleId><ArticleId IdType="pmc">PMC4431681</ArticleId><ArticleId IdType="pubmed">25974040</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstr&#xf8;m K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirj&#xe1;k L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kum&#xe1;novics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, R&#xfa;a-Figueroa Fern&#xe1;ndez &#xcd;, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, D&#xf6;rner T, Johnson SR. (2019). European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400&#x2013;1412. doi: 10.1002/art.40930. Epub 2019 Aug 6. PMID: 31385462; PMCID: PMC6827566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y, Rahman A, Prabu A, Akil M, McHugh N, Edwards C, D&#x2019;Cruz D, Khamashta MA, Gordon C. (2010). The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2011 May;50(5):982-8. doi: 10.1093/rheumatology/keq376. Epub 2011 Jan 18. PMID: 21245073; PMCID: PMC3077910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077910</ArticleId><ArticleId IdType="pubmed">21245073</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam GKW, Petri M. (2005). Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005;23(5 Suppl 39):S120&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">16273796</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinf (Oxford England) 2013;29(1):15&#x2013;21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;40. doi: 10.1093/bioinformatics/btp616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan AB, Jenkins SL, Jagodnik KM et al. (2018). The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. Cell Syst. 2018;6(1):13&#x2013;24. doi:10.1016/j.cels.2017.11.001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5799026</ArticleId><ArticleId IdType="pubmed">29199020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. New York, N.Y.): Science; 2006. pp. 1929&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008526</ArticleId></ArticleIdList></Reference><Reference><Citation>Csardi G, Nepusz T. (2006). The igraph software package for complex network research.InterJournal, Complex Systems,1695. https://igraph.org.</Citation></Reference><Reference><Citation>Epskamp S, Cramer AOJ, Waldorp LJ, Schmittmann VD, Borsboom D. qgraph: network visualizations of Relationships in Psychometric Data. J Stat Softw. 2012;48(4):1&#x2013;18. doi: 10.18637/jss.v048.i04.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v048.i04</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI. (2008). An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 2008 May;58(5):1433-44. doi: 10.1002/art.23428. PMID: 18438845.</Citation><ArticleIdList><ArticleId IdType="pubmed">18438845</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. (2010). Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 2010 Jul;62(7):2086-92. doi: 10.1002/art.27452. PMID: 20222110; PMCID: PMC2902591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902591</ArticleId><ArticleId IdType="pubmed">20222110</ArticleId></ArticleIdList></Reference><Reference><Citation>Du P, Zhang W, Cui H, He W, Lu S, Jia S, Zhao M. Sulforaphane Ameliorates the Severity of Psoriasis and SLE by Modulating Effector Cells and Reducing Oxidative Stress.Front Pharmacol. 2022 Jan21;13:805508. doi: 10.3389/fphar.2022.805508. PMID: 35126161; PMCID: PMC8814458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814458</ArticleId><ArticleId IdType="pubmed">35126161</ArticleId></ArticleIdList></Reference><Reference><Citation>Berrahmoune H, Lamont JV, Herbeth B, FitzGerald PS, Visvikis-Siest S. (2006). Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: Results from the STANISLAS cohort. Clin Chem. 2006 Mar;52(3):504 &#x2013; 10. doi: 10.1373/clinchem.2005.055798. Epub 2006 Jan 19. PMID: 16423909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16423909</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngamjanyaporn P, Worawichawong S, Pisitkun P, Khiewngam K, Kantachuvesiri S, Nongnuch A, Assanatham M, Sathirapongsasuti N, Kitiyakara C. Predicting treatment response and clinicopathological findings in lupus nephritis with urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratios. PLoS One 2022 Mar. 2022;10(3):e0263778. doi: 10.1371/journal.pone.0263778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263778</ArticleId><ArticleId IdType="pmc">PMC8912200</ArticleId><ArticleId IdType="pubmed">35271583</ArticleId></ArticleIdList></Reference><Reference><Citation>Basler M, Claus M, Klawitter M, Goebel H, Groettrup M. Immunoproteasome Inhibition Selectively Kills Human CD14+ Monocytes and as a Result Dampens IL-23 Secretion. J Immunol. 2019 Oct 1;203(7):1776&#x2013;1785. doi: 10.4049/jimmunol.1900182. Epub 2019 Sep 4. PMID: 31484727.</Citation><ArticleIdList><ArticleId IdType="pubmed">31484727</ArticleId></ArticleIdList></Reference><Reference><Citation>Soerensen H, Schneidewind-Mueller JM, Lange D, Kashiwagi N, Franz M, Yokoyama T, Ramlow W. (2006). Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol Int. 2006 Mar;26(5):409 &#x2013; 15. doi: 10.1007/s00296-005-0031-1. Epub 2005 Sep 28. PMID: 16189656.</Citation><ArticleIdList><ArticleId IdType="pubmed">16189656</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T, Harada M. (2004). Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford). 2004 Sep;43(9):1121-8. doi: 10.1093/rheumatology/keh277. Epub 2004 Jun 22. PMID: 15213333.</Citation><ArticleIdList><ArticleId IdType="pubmed">15213333</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers SA, Wen J, Shum J, Doerner J, Herlitz L, Putterman C. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus. Clin Immunol. 2017 Dec;185:100&#x2013;8. 10.1016/j.clim.2016.08.019. Epub 2016 Aug 26. PMID: 27570219; PMCID: PMC5326697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5326697</ArticleId><ArticleId IdType="pubmed">27570219</ArticleId></ArticleIdList></Reference><Reference><Citation>Buang N, Tapeng L, Gray V, Sardini A, Whilding C, Lightstone L, Cairns TD, Pickering MC, Behmoaras J, Ling GS, Botto M. Type I interferons affect the metabolic fitness of CD8 + T cells from patients with systemic lupus erythematosus. Nat Commun. 2021 Mar 31;12(1):1980. doi: 10.1038/s41467-021-22312-y. PMID: 33790300; PMCID: PMC8012390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012390</ArticleId><ArticleId IdType="pubmed">33790300</ArticleId></ArticleIdList></Reference><Reference><Citation>Panwar B, Schmiedel BJ, Liang S, White B, Rodriguez E, Kalunian K, McKnight AJ, Soloff R, Seumois G, Vijayanand P, Ay F. Multi-cell type gene coexpression network analysis reveals coordinated interferon response and cross-cell type correlations in systemic lupus erythematosus.Genome Res. 2021Apr;31(4):659&#x2013;676. doi: 10.1101/gr.265249.120. Epub 2021 Mar 5. PMID: 33674349; PMCID: PMC8015858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015858</ArticleId><ArticleId IdType="pubmed">33674349</ArticleId></ArticleIdList></Reference><Reference><Citation>Geyer CE, Newling M, Sritharan L, Griffith GR, Chen HJ, Baeten DLP, den Dunnen J. C-Reactive Protein Controls IL-23 Production by Human Monocytes.Int J Mol Sci. 2021 Oct28;22(21):11638. doi: 10.3390/ijms222111638. PMID: 34769069; PMCID: PMC8583945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8583945</ArticleId><ArticleId IdType="pubmed">34769069</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith S, Fernando T, Wu PW, Seo J, N&#xed; Gabhann J, Piskareva O, McCarthy E, Howard D, O&#x2019;Connell P, Conway R, Gallagher P, Molloy E, Stallings RL, Kearns G, Forbess L, Ishimori M, Venuturupalli S, Wallace D, Weisman M, Jefferies CA. MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. J Autoimmun. 2017 May;79:105&#x2013;11. Epub 2017 Mar 17. PMID: 28318807.</Citation><ArticleIdList><ArticleId IdType="pubmed">28318807</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong DK, Shi X, Han MM, Zhang XM, Wu NN, Sheng XY, Wang JN. The regulatory mechanism and potential application of IL-23 in autoimmune diseases.Front Pharmacol. 2022 Sep13;13:982238. doi: 10.3389/fphar.2022.982238. PMID: 36176425; PMCID: PMC9514453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9514453</ArticleId><ArticleId IdType="pubmed">36176425</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohlmeyer CW, Shang C, Han P, Cui ZH, Jones RM, Clarke AS, Murray BP, Lopez DA, Newstrom DW, Inzunza MD, Matzkies FG, Currie KS, Di Paolo JA. (2021). Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis. BMC Rheumatol. 2021 Mar 30;5(1):15. doi: 10.1186/s41927-021-00178-3. PMID: 33781343; PMCID: PMC8008554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008554</ArticleId><ArticleId IdType="pubmed">33781343</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>